AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
AtriCure (Nasdaq: ATRC), a leader in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The event will take place on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. AtriCure’s management will present at this conference. Interested individuals can access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure (Nasdaq: ATRC), un leader nei trattamenti e nelle terapie chirurgiche per la fibrillazione atriale (Afib), la gestione dell'appendice atriale sinistra (LAA) e la gestione del dolore post-operatorio, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan.
L'evento si svolgerà mercoledì 15 gennaio 2025, alle 15:00 ora del Pacifico. Il management di AtriCure presenterà a questa conferenza. Gli interessati possono accedere a un webcast audio dal vivo della presentazione visitando la sezione “Investitori” del sito web dell'azienda all'indirizzo https://ir.atricure.com.
AtriCure (Nasdaq: ATRC), un líder en tratamientos y terapias quirúrgicas para la fibrilación auricular (Afib), la gestión de la orejuela auricular izquierda (LAA) y el manejo del dolor postoperatorio, anunció su participación en la 43ª Conferencia Anual de Salud J.P. Morgan.
El evento tendrá lugar el miércoles 15 de enero de 2025, a las 3:00 pm, hora estándar del Pacífico. La dirección de AtriCure presentará en esta conferencia. Las personas interesadas pueden acceder a una transmisión de audio en vivo de la presentación visitando la sección “Inversionistas” en el sitio web de la empresa en https://ir.atricure.com.
AtriCure (Nasdaq: ATRC)는 심방세동(Afib), 좌심방 부속기(LAA) 관리 및 수술 후 통증 관리에 대한 외과적 치료 및 요법의 선두주자로, 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
이 행사는 2025년 1월 15일 수요일 오후 3시 태평양 표준시에 개최됩니다. AtriCure의 경영진이 이 컨퍼런스에서 발표할 예정입니다. 관심 있는 분들은 회사 웹사이트의 “투자자” 섹션을 방문하여 발표의 실시간 오디오 웹캐스트를 접속할 수 있습니다: https://ir.atricure.com.
AtriCure (Nasdaq: ATRC), un leader dans les traitements et thérapies chirurgicales pour la fibrillation auriculaire (Afib), la gestion de l'appendice auriculaire gauche (LAA) et la gestion de la douleur post-opératoire, a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan sur la Santé.
L'événement aura lieu le mercredi 15 janvier 2025, à 15h00, heure normale du Pacifique. La direction d'AtriCure fera une présentation à cette conférence. Les personnes intéressées peuvent accéder à un webcast audio en direct de la présentation en visitant la section « Investisseurs » du site web de l'entreprise à l'adresse https://ir.atricure.com.
AtriCure (Nasdaq: ATRC), ein führendes Unternehmen in der chirurgischen Behandlung und Therapie von Vorhofflimmern (Afib), dem Management des linken Vorhofohrechens (LAA) und der postoperativen Schmerztherapie, gab seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare bekannt.
Die Veranstaltung findet am Mittwoch, den 15. Januar 2025, um 15:00 Uhr Pazifischer Standardzeit statt. Die Geschäftsführung von AtriCure wird auf dieser Konferenz präsentieren. Interessierte Personen können die Live-Audioübertragung der Präsentation abrufen, indem sie den Bereich „Investoren“ auf der Unternehmenswebsite unter https://ir.atricure.com besuchen.
- None.
- None.
AtriCure’s management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241223034729/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
marissa@gilmartinir.com
Source: AtriCure, Inc.
FAQ
When will AtriCure present at the J.P. Morgan Healthcare Conference?
How can I access the live webcast of AtriCure's presentation at the J.P. Morgan Healthcare Conference?
What topics will AtriCure cover at the J.P. Morgan Healthcare Conference?
What is the stock symbol for AtriCure?
Where is AtriCure headquartered?
What is the significance of AtriCure's participation in the J.P. Morgan Healthcare Conference?
